Chongqing Lummy Pharmaceutical Co., Ltd. (SHE:300006)
China · Delayed Price · Currency is CNY 5.09
+0.12 (2.41%)
Feb 3, 2026, 3:04 PM CST
SHE:300006 Revenue
Chongqing Lummy Pharmaceutical had revenue of 203.87M CNY in the quarter ending September 30, 2025, a decrease of -8.95%. This brings the company's revenue in the last twelve months to 771.02M, down -9.98% year-over-year. In the year 2024, Chongqing Lummy Pharmaceutical had annual revenue of 795.60M, down -11.17%.
Revenue (ttm)
771.02M
Revenue Growth
-9.98%
P/S Ratio
6.81
Revenue / Employee
756.64K
Employees
1,019
Market Cap
5.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 795.60M | -99.99M | -11.17% |
| Dec 31, 2023 | 895.59M | 11.01M | 1.24% |
| Jan 1, 2023 | 884.59M | -340.64M | -27.80% |
| Dec 31, 2021 | 1.23B | -358.31M | -22.63% |
| Dec 31, 2020 | 1.58B | -275.48M | -14.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 53.89B |
| Zhejiang Int'l Group | 33.54B |
| Shanghai Shenqi Pharmaceutical Investment Management | 1.88B |
| GuangYuYuan Chinese Herbal Medicine | 1.39B |
| Shanghai InnoStar Bio-tech | 829.92M |
| Hangzhou Minsheng Healthcare | 744.06M |
| Hangzhou Bio-Sincerity Pharma-Tech | 590.33M |
| Zhejiang Haisen Pharmaceutical | 510.33M |